Understand CLIA certification tiers, staffing requirements, and how to determine whether your testing operation actually needs a CLIA waiver — before you apply.
The Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing by classifying tests into complexity tiers. Each tier carries its own certification requirements, staffing qualifications, and oversight standards. Here's what you need to know.
It's not about your state. It's about which type of test device you're using.
Instant drug test devices are sold in two regulatory categories — and the labeling on the box decides whether CLIA applies.
Marketed and labeled for non-clinical use — employment, workplace, legal, insurance, athletic.
NOT FDA-cleared for clinical use. Used by most TPAs, employers, and workplace testing programs.
→ No CLIA Certificate of Waiver required.
FDA-cleared for clinical / medical use — clinics, treatment programs, anywhere results inform medical decisions.
Used in healthcare settings, MRO offices, rehab programs, occupational health.
→ CLIA Certificate of Waiver required if read onsite.
Source: Official CMS guidance — CMS CLIA Certification brochure (revised March 2026). See also FDA CLIA Database for the current waived-analyte list.
One of the most common — and costly — misunderstandings in workplace testing. Reading an instant device is a collector function, not a lab result.
An instant cup, dip card, or oral-fluid device gives a presumptive screening result — not a confirmed one. There are only two correct things to do with it:
No detectable presence on the panel. This is the only outcome a screening device can resolve on its own — and it's why instant testing saves non-DOT employers time and money.
A presumptive positive must be sent to a certified laboratory for confirmation by GC/MS or LC/MS/MS, then reviewed by a Medical Review Officer (MRO) before anyone is told a "positive."
Sources: SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs (initial/screen test vs. confirmatory test); for DOT testing, the screen-then-confirm-then-MRO sequence is required by 49 CFR Part 40 (§§ 40.91–40.97, 40.123). Non-DOT programs follow the same screen-then-confirm best practice.
Answer 4 quick questions — including the critical one about your test device — and we'll give you a clear answer for your situation.
Question 1 of 4
Question 2 of 4
Question 3 of 4
Check the box, package insert, or manufacturer's product page. This is the single most important factor.
Question 4 of 4
New York and Washington have their own HHS-approved state programs (per the CMS CLIA brochure). California, Maryland, Pennsylvania, and Rhode Island require additional state-level licensing on top of federal CLIA where CLIA applies.
—
This tool gives a general answer based on federal CLIA rules and known state licensing programs. Always confirm with your state's CLIA agency before relying on a particular path — find their contact info in the CLIA State Directory.
There's an important exemption that applies specifically to drug testing — here's what it means for you.
This exemption applies to the laboratory that analyzes the specimen, not to upstream collection sites. If a lab is certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) and its drug testing follows SAMHSA guidelines, that lab is not required to hold a CLIA certificate for that drug testing.
Important: This exemption covers SAMHSA-regulated drug testing performed at the certified lab. Any other testing at the same facility still requires CLIA certification. Collection-only operations (collect & ship) are separately outside CLIA because they don't perform the test.
Per CMS, "any laboratory that only performs testing for forensic purposes" is exempt from CLIA — the example CMS gives is criminal investigations. The industry has long applied the same logic to workplace drug testing performed with FUO (Forensic Use Only) labeled devices, since those tests are not used for clinical diagnosis or treatment.
The purpose of the test — and the device labeling — is what determines whether CLIA applies, not the act of testing itself.
If you've decided you need one — i.e., you plan to read FDA-cleared / CLIA-Waived devices onsite for clinical purposes — here's the federal application process.
Per the CMS CLIA brochure (March 2026), two states operate their own HHS-approved laboratory programs:
Washington — Medical Test Site (MTS) program replaces federal CLIA. Do NOT submit Form CMS-116.
New York — partial exemption. Contact the state agency to determine what applies.
These states require state-level licensing in addition to federal CLIA (where CLIA applies):
California, Maryland, Pennsylvania, Rhode Island. California specifically applies to specimens shipped to a clinical lab — not to onsite workplace testing using FUO devices. See the State Directory for each agency's rules.
Each fixed location where you perform testing requires its own CLIA certificate.
Mobile units (health fairs, temporary screening sites) may operate under the certificate of their designated primary site — no separate certificate needed.
You must notify your State Agency within 30 days if any of the following change:
If you want to add moderate or high complexity testing later, you must reapply using the same Form CMS-116 — and cannot begin that testing until the new certificate is received.
Your CLIA waiver covers your lab testing — make sure your collectors are DOT-qualified and your business is accredited and listed.